# REFINE-Lung (NCT05085028)

> A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: first-line advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05085028
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Imperial College London
- Conditions: Lung Cancer, Nonsmall Cell
- Interventions: Pembrolizumab 25 MG/ML [Keytruda]
- Enrollment: 1750
- Primary outcome: Overall survival at 2 years

## Indexed commentary on REFINE-Lung so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 3 podcast episodes
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=refine-lung-nct05085028

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05085028", "email": "<work email>"}; the inbox owner confirms by the emailed link.
